<article>Chinese biotherapeutics platform Hangzhou Just Biotherapeutics (HJB) has secured a $35 million Series B+ round led by Beijing and Hong Kong-based private equity firm Hillhouse Capital.</article>

Chinese biotherapeutics platform Hangzhou Just Biotherapeutics (HJB) has secured a $35 million Series B+ round led by Beijing and Hong Kong-based private equity firm Hillhouse Capital.
Existing investors such as Temasek, Lilly Asia Ventures, ARCH Venture Partners, Taikang and BOCGI Zheshang Capital also participated in this round. This brings the total funding of HJB to over $120 million. 
&#8220;With this additional investment, we will be able to ramp up our clinical R&amp;D capabilities globally and boost our pipeline by engaging in broader partnerships. We are now on our way to beginning global clinical trials for several of our assets,&#8221; said HJB founder and CEO Yining Zhao.
HJB is focused on the completion of its R&amp;D centre and manufacturing facility in Hangzhou, establishing its R&amp;D and clinical development capabilities, and building a strong team, a statement said.
&#8220;Innovative medicine has great market growth potential because it can truly create value for society, serving patients in and outside China&#8230; We appreciate HJB&#8217;s capabilities and promising future in the field of bio-pharmaceutical research and development and are willing to support the firm&#8217;s long-term growth using the principles and methods of value investing,&#8221; said Hillhouse Capital in a statement.
The bio-healthcare firm haan closed a RMB400 million ($59 million) Series B round led by Singapore state invesment firm Temasek Holdings <a href="https://www.dealstreetasia.com/stories/temasek-just-biochina-series-b-79831/">last August</a>.
An affiliate of Seattle-based Just Biotheraperutics, HJB was founded in 2016 by former Amgen and Genentech executives in Hangzhou, China to develop global antibody and recombinant protein biotheraperutics. Its pipeline consists of assets in the areas of oncologics, genetic rare diseases and metabolic diseases. 
Also Read: 
<a style="color: #ff0000;" href="https://www.dealstreetasia.com/stories/temasek-just-biochina-series-b-79831/">Temasek leads $59 million Series B in biotech firm Just China</a>
<a style="color: #ff0000;" href="https://www.dealstreetasia.com/stories/china-sequoia-jhl-biotech-98675/">China: Sequoia-backed biopharma startup JHL Biotech raises $106m</a>

Hangzhou Just Biotherapeutics (HJB) has secured a $35 million Series B+ round led by Beijing and Hong Kong-based private equity firm Hillhouse Capital.

Temasek-backed Hangzhou Just Biotherapeutics closes $35m Series B+ round

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Temasek-backed Hangzhou Just Biotherapeutics closes $35m Series B+ round

Start your deal-making journey now!

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief